Corcept Therapeutics Incorporated (NASDAQ: CORT) is subject to a securities class action lawsuit following the FDA's rejection of its drug ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE